期刊文献+

卵巢浆液性癌中K-ras基因突变和p21、p53蛋白的表达 被引量:3

K-ras mutations and expression of p21, p53 proteins in ovarian serous carcinoma
下载PDF
导出
摘要 目的研究卵巢浆液性癌及交界性病变中的K-ras基因第1外显子第12号密码子的点突变及p21和p53蛋白的表达,探讨其与卵巢浆液性癌癌变的关系。方法应用显微切割、PCR-RFLP和免疫组织化学技术,对30例卵巢浆液性癌及其交界性病变区的K-ras基因突变及p21和p53蛋白表达进行研究。结果卵巢浆液性癌K-ras基因突变率为17.8%,交界性病变为12.5%,良性病变未检测出突变。浆液性癌p53蛋白表达率为66.7%,明显高于交界性病变的37.5%。p21蛋白在浆液性癌的表达率为33.3%,明显低于交界性病变的87.5%。结论K-ras基因突变主要发生于低分级浆液性癌中,是其发生的早期分子事件。p53和p21蛋白在浆癌中表达呈明显的负相关,提示突变型p53基因失去诱导p21的基因表达及其负性调控作用可能是导致细胞持续恶性增殖而癌变的原因。 Objective To study K-ras mutations and expression of p21, p35 proteins in ovarian carcinoma, and its relationships. Methods K-ras mutations and expressions of p21 and p53 proteins were detect- ed in 30 cases of ovarian serous carcinomas with microdissection technique and PCR-RFLP and immunohisochemical techniq-ue. Results The expression of p53 in ovarian carcinoma was 66.7%, that significantly higher than borderline malignancy. While p21 protein in ovarian carcinoma was 33.3%, that significantly low- er than borderline malignancy. Conclusions K-ras mutations in serous ovarian carciuoma are very few and correlated with the low-grade carcinoma, p53 gene is mostly correlated with the high-grade ovarian carcinoma through losing inducement with p21 gene.
出处 《现代实用医学》 2007年第7期518-520,共3页 Modern Practical Medicine
基金 宁波市科技局医学科研项目计划立项课题 项目编号:200562
关键词 卵巢肿瘤 K-RAS基因 P21蛋白 P53蛋白 Ovarian carcinoma K-ras p53 protein p21 protein
  • 相关文献

参考文献7

  • 1Zhuang Z,Berheau P,Emmert-Buck MR,et al.A microdissection technique for archival DNA analysis of specific cell populations in lesions <1mm in size[J].Am J Pathol,1995,146(3):620-625.
  • 2潘晓琳,高志斌,陆天才,李洪安,郑兴征.卵巢癌中k-ras基因点突变及p53蛋白表达[J].临床与实验病理学杂志,2005,21(1):66-69. 被引量:15
  • 3Cheng EJ,Kurman RJ,Wang M,et al.Molecular genetic analysis of ovari an serous cystadeno-mas[J].Lab Invest,2004,84 (6):778-784.
  • 4Hass CJ,Diebold J,Hirschmann A,et al.In serous ovarian neoplasms the frequency of K-ras mutations correlates with their malignant potential[J].Virchow Archir,2003,434 (2):117-120.
  • 5Singer G,Oldt R,Cohen Y,et al.Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma[J].J Natl Cancer Inst,2003,95 (60):484-486.
  • 6廖冰,薛玲,车丽洪,吴惠茜.p53、p21^(ras)和connexin43蛋白在卵巢浆液性囊腺癌中的表达及意义[J].临床与实验病理学杂志,2006,22(4):498-499. 被引量:8
  • 7Geisler HE,Geisler JP,Miller GA,et al.p21 and p53 in ovarian carcinoma:their combined staining is more valuable than either alone[J].Cancer,2001,92 (4):781-786.

二级参考文献27

  • 1潘晓琳,高志斌,陆天才,李洪安,郑兴征.卵巢癌中k-ras基因点突变及p53蛋白表达[J].临床与实验病理学杂志,2005,21(1):66-69. 被引量:15
  • 2Jiang W,Kahn SM,Guillem JG,et al. Rapid detection of ras oncogenes in human tumors: applications to colon,esophageal,and gastric cancer[J]. Oncogene,1989,4(7): 923-8.
  • 3Yanagisawa A,Ohtake K,Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation[J]. Cancer Res,1993,53(5): 953-6.
  • 4Fujita M,Enomoto T,Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes[J]. Mol Cell Endocrinol,2003,202(1-2):97-9.
  • 5Mandai M,Konoshi I,Kuroda H,et al. Heterogeneous distribution of k-ras mutated epithelia in mucinous ovarian tumors with special reference to histopathology[J]. Hum Pathol,1998,29(1):34-40.
  • 6Pellegata NS,Sessa F,Renault B,et al. k-ras and p53 gene mutation in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions[J]. Cancer Res,1994,54(6):1556-60.
  • 7Maeshima A,Miyagi A,Hirai T,et al. Mucin-producing adenocarcinoma of the lung,with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation[J]. Pathol Int,1997,47(7):454-60.
  • 8Cuatrecasas M,Matias-Guiu X,Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with psuedomyxoma peritonei[J]. Am J Surg Pathol,1996,20(6):739-46.
  • 9Matias-Guiu X,Prat J. Molecular pathology of ovarian carcinoma[J]. Virchows Arch,1998,443(2):103-11.
  • 10Takeshima YK,Vishwa JA. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection[J]. Hum Pathol,2001,32(11):1203-8.

共引文献21

同被引文献32

  • 1俞琳玲,石一复,王吉达,潘芝梅.原发性输卵管癌的CT征象分析[J].中华肿瘤杂志,2004,26(5):318-319. 被引量:26
  • 2李艳红,张伟,朱少君,巩丽,杨瑛,李爱宁,兰淼.抑癌基因p16和转移抑制基因nm23在卵巢上皮性肿瘤中的表达[J].现代肿瘤医学,2006,14(6):735-737. 被引量:4
  • 3姚德生,李力,Kenneth Garson,Barbara C. Vanderhyden.癌基因c-myc和K-ras在卵巢癌发生发展中的作用[J].广西医科大学学报,2006,23(3):371-374. 被引量:2
  • 4方志文,牟召霞,王新艳,翟玉栋.p53与c-myc和cyclin B_1在卵巢上皮性癌组织中的表达及意义[J].中华肿瘤防治杂志,2007,14(4):284-286. 被引量:22
  • 5Reuter CW,Morgan MA,Bergmann L.Targeting the Ras signalingpathway:a rational,m ecbanism based treat ment forhema tologicmalignancies[J].Blood,2000,96(5):1655-1669.
  • 6Hass CJ,Diebold J,Hirschmann A,et al.In serous ovarian Neoplasmsthe frequency of K-ras mutations correlates with their malignantpotential[J].Virchhow Archir,2003,434(2):117-120.
  • 7Oster SK,Mao DY,Kennedy J,et al.Functional analysis of the N-terminal domain of the Myc oncoprotein[J].Oncogene,2003,22(13):1998-2010.
  • 8Schmidt EV.The role of c-myc in regulation of translation[J].Oncogene,2004,23(18):3217-3221.
  • 9Albrechtsen N,Dornreiter I,Grosse F,et al.Extra c-myc oncogene copies in high risk cutaneous malignant melano ma and melanoma metastases[J].British J Cancer,2001,84(1):72-79.
  • 10HarlozinskaA,Bar J K,et al.p53,c-erbB-2 and p21ras expression in tumor effusion cells of patients with histopathologically different ovarian neoplasms.Anticancer-Res[J].1997,17(5A):3545.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部